Literature DB >> 2808058

Postoperative radiotherapy in the management of cancer of the maxillary sinus.

M Zaharia1, L E Salem, R Travezan, A Moscol, L Pinillos, C Farias, L Pinillos.   

Abstract

This report comprises 149 patients with carcinoma of the maxillary sinus treated with radical surgery and postoperative radiotherapy (5500 to 6000 cGy in 6 weeks) between 1963 and 1980 at the Instituto Nacional de Enfermedades Neoplasicas of Lima. Permanent local control was observed in 67.1% of the cases with a 5-year actuarial survival of 36.2% and a corrected survival for death not due to cancer of 42.3%. The ultimate local and distant failures were 61%. Data were analyzed regarding stage of the disease, radiotherapeutic technique and its influence on local control, complications, and patterns of relapse. The data indicate that the stage of the tumor influences survival. Because of the natural history of this disease, local control is paramount.

Entities:  

Mesh:

Year:  1989        PMID: 2808058     DOI: 10.1016/0360-3016(89)90143-0

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  3 in total

Review 1.  Squamous cell carcinoma at maxillary sinus: clinicopathologic data in a single Brazilian institution with review of literature.

Authors:  Marcello Roter M Santos; João Paulo S Servato; Sérgio Vitorino Cardoso; Paulo Rogério de Faria; Ana Lúcia A Eisenberg; Fernando Luiz Dias; Adriano Mota Loyola
Journal:  Int J Clin Exp Pathol       Date:  2014-12-01

2.  The Role of Full-Thickness Skin Grafts in Patient's Rehabilitation after Maxillectomy and Midface Defects.

Authors:  Iwona Niedzielska; Łukasz Obszyński; Michał Bąk; Damian Niedzielski
Journal:  J Clin Med       Date:  2022-06-22       Impact factor: 4.964

3.  Rare tumors of sinonasal track.

Authors:  Darshan V Doshi; Umank Tripathi; Rajendra I Dave; Shashank J Pandya; Hemant K Shukla; Bhavana C Parikh
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2010-09-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.